Smith & Nephew plc

Research Smith & Nephew plc (SNN) on Bullrun: market cap USD 12.43B, dividend yield 2.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 12.43B; dividend yield is 2.7%.

Peer valuation comparison

Latest dividend yield is 2.68% versus a Healthcare sector median of 2.11% (27.0% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 6.16BUSD 625.00MUSD 852.00M68.0%1.43USD 557.00MUSD 3.33BUSD 5.29B
FY2024USD 5.81BUSD 412.00MUSD 606.00M69.6%0.94USD 619.00MUSD 3.32BUSD 5.27B
FY2023USD 5.55BUSD 263.00MUSD 181.00M68.8%0.6USD 302.00MUSD 3.08BUSD 5.22B
FY2022USD 5.22BUSD 223.00MUSD 110.00M70.5%0.5USD 350.00MUSD 2.87BUSD 5.26B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 12.43Bn/a2.7%0.78
20252025-12-31USD 13.93Bn/a2.3%0.76
20242024-12-31USD 10.74Bn/a3.1%0.75
20232023-12-29USD 11.87Bn/a2.7%0.75
20222022-12-30USD 11.68Bn/a2.8%0.75
20212021-12-31USD 15.20Bn/a2.2%0.75

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.78 USD, yield 2.7%.

YearDividends/share
FY20250.76 USD
FY20240.75 USD
FY20230.75 USD
FY20220.75 USD
FY20210.75 USD

About Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Smith & Nephew plc's market cap?

Smith & Nephew plc's market capitalization is USD 12.43B.

Does Smith & Nephew plc pay a dividend?

Smith & Nephew plc has a dividend yield of 2.7%.

What does Smith & Nephew plc do?

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.